MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.

 
 
NASDAQ: MGNX
29.26
Change:
+0.02 (+0.07%)
Day High:
30.14
Day Low:
28.55
Volume:
194104.00
4:00 PM ET on Aug 25, 2016 Delayed at least 20 minutes.. Provided by eSignal

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close